1006 studies found for:    "Macular degeneration"
Show Display Options
Rank Status Study
21 Unknown  Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Device: Ocular Brachytherapy
22 Not yet recruiting Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab 0.5mg
23 Terminated 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: pazopanib eye drops
24 Completed
Has Results
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Macugen
25 Not yet recruiting A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
Condition: Neovascular Macular Degeneration
Intervention: Drug: Aflibercept
26 Completed Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Other: Proton beam irradiation and ranibizumab
27 Completed Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: AdGVPEDF.11D
28 Completed Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Palomid 529
29 Completed
Has Results
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab
30 Completed Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL;   Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL;   Other: Anecortave Acetate Vehicle
31 Active, not recruiting Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Conditions: Macular Degeneration;   Age-Related Maculopathies;   Age-Related Maculopathy;   Maculopathies, Age-Related;   Maculopathy, Age-Related;   Retinal Degeneration;   Retinal Neovascularization;   Gene Therapy;   Therapy, Gene;   Eye Diseases
Intervention: Biological: AAV2-sFLT01
32 Completed A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Pazopanib
33 Not yet recruiting Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506);   Procedure: Sham IVT;   Drug: Ranibizumab;   Drug: Placebo
34 Completed Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
Condition: Macular Degeneration
Intervention: Drug: Celecoxib
35 Completed Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
36 Completed A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
37 Completed Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Interventions: Drug: Ketorolac + Ranibizumab;   Drug: Ranibizumab
38 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab;   Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
39 Completed A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
40 Completed
Has Results
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years